Blogs
May 4, 2026
Peter Lynch's Price-to-Earnings-to-Growth ratio reframes valuation: a high P/E may be cheap if growth is high, a low P/E may be a trap if growth is fading. Using Titan Biotech FY25 audited inputs (10-yr revenue CAGR ~15%, 10-yr PAT CAGR ~29%, CFO/Operating Profit ~103%) as a clean educational illustration.
May 4, 2026
Walter Schloss compounded 16% for 47 years from a back office, with no MBA, no Bloomberg terminal, and no management visits. Seven of his 16 factors illustrated through Titan Biotech FY25's audited balance sheet.
May 3, 2026
Daniel Kahneman and Dan Lovallo's 1993 distinction between the Inside View (story-driven) and the Outside View (reference-class base rates) is the most powerful behavioural upgrade an Indian long-term investor can make. We illustrate it with Titan Biotech's FY25 audited numbers, presented strictly as an educational case study of management process — not a valuation call.
May 3, 2026
The Beneish M-Score is the 8-variable forensic-accounting model published in 1999 that flagged Enron in 1998 — three years before bankruptcy. Learn how to compute it from any Indian annual report, and see why Titan Biotech FY25's 103% CFO/Operating Profit, ₹3 Cr borrowings, ₹7.78 Cr contingent liabilities and 14 board meetings sit deep in the 'unlikely manipulator' zone.
